Retrospective cohort study shows trimethoprim-sulfamethoxazole improves symptoms in children, suggesting effective treatment options in resistant areas.
SXT effectively alleviates clinical symptoms of pertussis in children in high MRBP prevalence regions. Nucleic acid negative conversion predicts clinical remission. An extended SXT course (10-14 days) demonstrates superior efficacy to a shorter course (5-7 days). No serious adverse events were observed; skin lesions were the most common side effect.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: